Could less treatment be more? trial tests spacing out breast cancer drugs
NCT ID NCT07401537
Summary
This study is for people with advanced triple-negative breast cancer whose disease is stable or shrinking after initial treatment. It aims to see if continuing immunotherapy with longer time between doses works as well as the standard schedule at keeping the cancer under control. The goal is to maintain effectiveness while potentially reducing side effects, improving quality of life, and lowering treatment burden.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Breast Tumor Center, Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.